SUZHOU, China, Dec. 3, 2025 /PRNewswire/ -- On December 3, 2025 (local time in Arizona, USA), ImmVira Group ("ImmVira" or the "Company") announced a poster presentation at the 26th Annual Meeting of the Society of Urologic Oncology (SUO 2025). The presentation featured the latest interim clinical data (as of September 19, 2025) for its lead HSV-1 oncolytic virus product. MVR-T3011, in high-risk BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) patients.

The patients were enrolled and treated with intravesical MVR-T3011 at two dose levels: 2x109 PFU and 1x1010 PFU in this study. There were a total of 26 patients with papillary (16 patients at the dosage level of 2x109 PFU, 10 patients at the dosage level of 1x1010 PFU), and a total of 12 patients with carcinoma in situ (CIS) (7 patients at the dosage level of 2x109 PFU, 5 patients at the dosage level of 1x1010 PFU) enrolled in this trial. Data from the patients demonstrated a promising efficacy profile:

(0) comments

Welcome to the discussion.

Keep it Clean. Please avoid obscene, vulgar, lewd, racist or sexually-oriented language.
PLEASE TURN OFF YOUR CAPS LOCK.
Don't Threaten. Threats of harming another person will not be tolerated.
Be Truthful. Don't knowingly lie about anyone or anything.
Be Nice. No racism, sexism or any sort of -ism that is degrading to another person.
Be Proactive. Use the 'Report' link on each comment to let us know of abusive posts.
Share with Us. We'd love to hear eyewitness accounts, the history behind an article.

Post a comment
Stop watching this discussion.